



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Terence H. W. Ching
✉ terence.ching@yale.edu

RECEIVED 17 January 2024
ACCEPTED 01 February 2024
PUBLISHED 16 February 2024

CITATION
Ching THW, Amoroso L, Bohner C,
D'Amico E, Eilbott J, Entezar T, Fitzpatrick M,
Fram G, Grazioplene R, Hokanson J,
Jankovsky A, Kichuk SA, Martins B, Patel P,
Schaer H, Shnayder S, Witherow C,
Pittenger C and Kelmendi B (2024)
Corrigendum: Safety, feasibility, tolerability,
and clinical effects of repeated psilocybin
dosing combined with non-directive support
in the treatment of obsessive-compulsive
disorder: protocol for a randomized, waitlist-
controlled trial with blinded ratings.
Front. Psychiatry 15:1372373.
doi: 10.3389/fpsy.2024.1372373

COPYRIGHT
© 2024 Ching, Amoroso, Bohner, D'Amico,
Eilbott, Entezar, Fitzpatrick, Fram, Grazioplene,
Hokanson, Jankovsky, Kichuk, Martins, Patel,
Schaer, Shnayder, Witherow, Pittenger and
Kelmendi. This is an open-access article
distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings

Terence H. W. Ching^{1*}, Lucia Amoroso¹, Calvin Bohner¹,
Elizabeth D'Amico¹, Jeffrey Eilbott¹, Tara Entezar¹,
Madison Fitzpatrick¹, Geena Fram¹, Rachael Grazioplene¹,
Jamila Hokanson¹, Anastasia Jankovsky¹, Stephen A. Kichuk¹,
Bradford Martins¹, Prerana Patel¹, Henry Schaer¹,
Sarah Shnayder¹, Chelsea Witherow¹, Christopher Pittenger^{1,2,3,4}
and Benjamin Kelmendi¹

¹Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States,

²Department of Psychology, Yale University, New Haven, CT, United States, ³Center for Brain and Mind Health, Yale University School of Medicine, New Haven, CT, United States, ⁴Child Study Center, Yale University School of Medicine, New Haven, CT, United States

KEYWORDS

obsessive-compulsive disorder, psilocybin, psychedelic, non-directive support, waitlist, treatment, mental health, adult psychiatry

A Corrigendum on

[Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings](#)

By Ching THW, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk SA, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C and Kelmendi B (2024) *Front. Psychiatry*. 14:1278823. doi: 10.3389/fpsy.2023.1278823

Error in Author List

In the published article, there was an error in the author list, and Anastasia Jankovsky was erroneously excluded. The corrected author list appears below.

Terence H. W. Ching,¹ Lucia Amoroso,¹ Calvin Bohner,¹ Elizabeth D'Amico,¹ Jeffrey Eilbott,¹ Tara Entezar,¹ Madison Fitzpatrick,¹ Geena Fram,¹ Rachael Grazioplene,¹ Jamila Hokanson,¹ Anastasia Jankovsky,¹ Stephen A. Kichuk,¹ Bradford Martins,¹ Prerana Patel,¹ Henry Schaer,¹ Sarah Shnayder,¹ Chelsea Witherow,¹ Christopher Pittenger,¹⁻⁴ Benjamin Kelmendi¹

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.